Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 116 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: High-Risk Localized Prostate Cancer Clear all
Terminated Early Phase 1 Interventional

Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer

NCT00499733
View directory record Official record
Conditions
Cancer
Interventions
cyclophosphamide, Cryoablation
Drug · Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 18, 2019 · Synced Oct 26, 2026, 2:22 PM EDT
Active, not recruiting Phase 3 Interventional

Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer

NCT02446444
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Enzalutamide, Conventional NSAA, LHRHA, External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost)
Drug · Radiation
Lead sponsor
University of Sydney
Other
Eligibility
18 Years and older · Male only
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 26, 2026, 2:22 PM EDT
Recruiting Not applicable Interventional

Focal Ablation With Focal Cryotherapy or HIFU for the Treatment of Men With Localized Prostate Cancer

NCT06178354
View directory record Official record
Conditions
Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8
Interventions
Cryosurgery, High-Intensity Focused Ultrasound Ablation, Survey Administration
Procedure · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 26, 2026, 2:22 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer

NCT00924469
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone, Leuprolide, Prednisone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Boston, Massachusetts • Houston, Texas • Seattle, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 26, 2026, 2:22 PM EDT
Withdrawn Not applicable Interventional

A Study of Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence

NCT04645810
View directory record Official record
Conditions
Prostate Cancer, HDR
Interventions
High-Dose-Rate Brachytherapy
Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 26, 2026, 2:22 PM EDT
Withdrawn Phase 2 Interventional

Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer

NCT04020094
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
MVA-BN-Brachyury
Combination Product
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 26, 2026, 2:22 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer

NCT07335796
View directory record Official record
Conditions
Prostate Cancer
Interventions
BMS-986165, Degarelix
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Montvale, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 26, 2026, 2:22 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

RYZ711 Diagnostic Platform Study

NCT07862582
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate, Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Biochemical Recurrence (BCR), High-Risk Localized Prostate Cancer
Interventions
RYZ711, PSMA PET/CT
Drug · Diagnostic Test
Lead sponsor
RayzeBio, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 26, 2026, 2:22 PM EDT
Completed Phase 2 Interventional Results available

Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer

NCT02064582
View directory record Official record
Conditions
Prostate Cancer
Interventions
Enzalutamide, Leuprolide acetate, radiation
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 12, 2020 · Synced Oct 26, 2026, 2:22 PM EDT
Recruiting Phase 3 Interventional

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

NCT06952803
View directory record Official record
Conditions
Prostate Cancer
Interventions
Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
45
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 26, 2026, 2:22 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer

NCT00828308
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ixabepilone, Prostatectomy
Drug · Procedure
Lead sponsor
Brown University
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 26, 2026, 2:22 PM EDT
Not listed Not applicable Interventional

Targeted Prostate Biopsy Using a Novel MRI-Ultrasound Fusion Device

NCT02524860
View directory record Official record
Conditions
Prostate Cancer
Interventions
Focal-Fusion Bx
Device
Lead sponsor
Focal Healthcare Inc.
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Sarasota, Florida
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 26, 2026, 2:22 PM EDT
Terminated Not applicable Interventional

Investigator Initiated Trial to Further Evaluate the Safety and Efficacy of Trans-perineal Focal Laser Ablation of Localized Prostate Cancer Using High Frequency Micro-ultrasound Imaging

NCT05826470
View directory record Official record
Conditions
Prostate Cancer, Low-risk or Favorable Intermediate Risk Prostate Cancer Who Are on an Active Surveillance Regimen
Interventions
TRANBERG®|Thermal Therapy System
Device
Lead sponsor
Genesis Research LLC
Network
Eligibility
40 Years to 85 Years · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 26, 2026, 2:22 PM EDT
Active, not recruiting Phase 3 Interventional

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

NCT02531516
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Apalutamide, Bicalutamide, Bicalutamide Placebo, Apalutamide Placebo, GnRH (agonist), 74-80 Grays (units of radiation)
Drug · Radiation
Lead sponsor
Aragon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
60
States / cities
Homewood, Alabama • Chandler, Arizona • Scottsdale, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 26, 2026, 2:22 PM EDT
Completed Phase 2 Interventional Results available

The Effect of High-dose Silybin-phytosome in Men With Prostate Cancer

NCT00487721
View directory record Official record
Conditions
Prostate Cancer
Interventions
Silibin-Phytosome
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 31, 2014 · Synced Oct 26, 2026, 2:22 PM EDT
Active, not recruiting Phase 1 Interventional

Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)

NCT04486755
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma
Interventions
Hypofractionated Radiation Therapy
Radiation
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 26, 2026, 2:22 PM EDT
Active, not recruiting Phase 3 Interventional

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

NCT04136353
View directory record Official record
Conditions
Prostate Cancer
Interventions
Darolutamide, Placebo oral tablet, Luteinizing Hormone-Releasing Hormone Analog, External Beam Radiotherapy
Drug · Radiation
Lead sponsor
University of Sydney
Other
Eligibility
18 Years and older · Male only
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
19
States / cities
Boston, Massachusetts • Brighton, Massachusetts • Burlington, Massachusetts + 15 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 26, 2026, 2:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Randomized Trial of HIFU vs. Cryo for Prostate Cancer

NCT06929065
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer Stage I, Prostate Cancer Stage II, High Intensity Focused Ultrasound, HIFU, Cryoablation
Interventions
HIFU vs Cryoablation
Procedure
Lead sponsor
Kaiser Permanente
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 26, 2026, 2:22 PM EDT
Withdrawn Not applicable Interventional

High-Intensity Focused Ultrasound in Treating Participants With Intermediate and High-risk Prostate Cancer

NCT03514927
View directory record Official record
Conditions
Prostate Cancer Stage I AJCC V6, Prostate Cancer Stage II, Prostate Cancer Stage III
Interventions
Contrast-Enhanced Ultrasound, High-Intensity Focused Ultrasound, Laboratory Biomarker Analysis, Multiparametric Magnetic Resonance Imaging, Radical Prostatectomy
Procedure · Device · Other
Lead sponsor
University of Southern California
Other
Eligibility
40 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2019 · Synced Oct 26, 2026, 2:22 PM EDT
Active, not recruiting Not applicable Interventional

Focal Salvage HDR Brachytherapy for Locally Recurrent Prostate Cancer in Patients Treated With Prior Radiotherapy

NCT03312972
View directory record Official record
Conditions
Locally Recurrent Prostate Cancer
Interventions
HDR Brachytherapy
Radiation
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
2
States / cities
Maywood, Illinois • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 26, 2026, 2:22 PM EDT
Withdrawn Phase 1 Interventional

Neoadjuvant Study of In-situ REIC/Dkk-3 in Prostate Cancer

NCT01197209
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ad-REIC/Dkk-3
Biological
Lead sponsor
Momotaro-Gene Inc.
Industry
Eligibility
20 Years to 75 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 26, 2026, 2:22 PM EDT
Active, not recruiting Phase 2 Interventional

Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma

NCT03436654
View directory record Official record
Conditions
Prostate Cancer
Interventions
Apalutamide, Abiraterone Acetate, Prednisone, GnRH agonist/antagonist
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
11
States / cities
Chicago, Illinois • Evanston, Illinois • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 26, 2026, 2:22 PM EDT
Recruiting No phase listed Observational

PRISM Study: Prostate Recurrence Detection Using Imaging With PSMA PET/MRI Post-high Intensity Focused Ultrasound

NCT07184970
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years to 95 Years · Male only
Enrollment
60 participants
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 26, 2026, 2:22 PM EDT
Recruiting Phase 2 Interventional

A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer

NCT06347705
View directory record Official record
Conditions
Prostate Cancer
Interventions
2141-V11 Antibody
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 26, 2026, 2:22 PM EDT